Subscribe

More Evidence Links Vitamin D Deficiency to Worse Outcomes in Breast Cancer

VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights - Clinical Research
Caroline Helwick

More evidence is accumulating that vitamin D levels play a role in breast cancer outcomes. Investigators from the United Kingdom reported that postmenopausal women with sufficient vitamin D levels were significantly less likely to develop bone metastases when taking zoledronic acid (Zometa) compared with women with lower vitamin D levels.

“Patients with a sufficient level of vitamin D had a better prognosis,” said Robert Coleman, MBBS, MD, FRCP, Professor, Department of Oncology, the University of Sheffield, England, and an Associate Director of the National Institute for Health Research Cancer Research Network in the United Kingdom. He called the findings “quite surprising.”

However, markers of bone turnover were not associated with risk, Dr Coleman added.

The findings came from an analysis of tissue samples from 872 participants of the large AZURE trial, which evaluated the efficacy of zoledronic acid in 3360 patients with early breast cancer. This subgroup analysis included 606 premenopausal women and 266 postmenopausal women.

AZURE showed little benefit in adding zoledronic acid to chemotherapy, but in a prespecified analysis, the postmenopausal women had a significantly lower risk of recurrence, in the bone and in distant sites, compared with premenopausal women. The current investigation sought to explore this, and looked at baseline levels of 2 markers of bone turnover (CTX and P1NP) as well as 25-hydroxyvitamin (25[OH])D as a marker of bone and general health.

The 25(OH)D level was deemed “insufficient” at ≤30 ng/mg and “sufficient” above this level. A striking finding was that only 10.3% of women had sufficient vitamin D levels, Dr Coleman reported.

Vitamin D Level Linked to Recurrence

Although neither of the 2 bone turnover markers predicted outcomes, there were “quite surprising differ­ences” in recurrence based on 25(OH)D levels, he said.

A low vitamin D level predicted the development of bone metastases, with a hazard ratio (HR) of 0.11 (P = .025). A low vitamin D level appeared to predict for distant recurrence as well, with an HR of 0.56, but this did not reach statistical significance.

Dr Coleman suggested that the findings have clinical implications. “Clinicians should be measuring vitamin D [and] replenishing it appropriately,” he noted. “But whether vitamin D as an intervention will change outcome, I don’t know.”

Carol A. Lange, PhD, coleader of the Women’s Cancer Research Pro­gram, Professor of the Departments of Medicine and Pharmacology, Tickle Family Land Grant Endowed Chair in Breast Cancer Research, and Director, Cancer Biology Training Grant of the University of Minnesota, Minneapolis, who moderated the session, agreed that “it’s a really good idea” to keep vitamin D levels in the sufficient range, noting that this is an inexpensive and apparently safe intervention.

Current studies are attempting to further elucidate the mechanism underlying vitamin D’s potential antitumor effects, Dr Lange said.—CH

Related Items
Can Some Patients with Multiple Sclerosis Stop Treatment?
Caroline Helwick
Web Exclusives published on August 30, 2017 in Multiple Sclerosis
Oral Ozanimod: A Safer Sphingosine-1-Phosphate Receptor Modulator?
Caroline Helwick
Web Exclusives published on June 26, 2017 in Multiple Sclerosis
Vitamin D Supplementation Shows Benefits in Multiple Sclerosis, but Questions Remain
Caroline Helwick
Web Exclusives published on March 31, 2017 in Multiple Sclerosis
Ocrelizumab Receives Breakthrough Therapy for Progressive Multiple Sclerosis
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Ozanimod Achieves Very Low Relapse Rate in MS
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Stem-Cell Transplantation Shows Promise in Multiple Sclerosis, but Major Concerns Remain
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Treatment of Psoriatic Arthritis Explored by Cost-Effectiveness
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Psoriatic Arthritis
Treatment Outcomes and Cost Assessed for Systemic Lupus Erythematosus
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Lupus
Ankylosing Spondylitis Treatment Costs Assessed
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Ankylosing Spondylitis
Patients with Myeloma Satisfied with Their Care but Feel Unprepared to Discuss Treatment Choices
Caroline Helwick
Value-Based Care in Myeloma published on February 26, 2015 in Multiple Myeloma
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology